Compare RELY & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | TMDX |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.9B |
| IPO Year | 2021 | 2019 |
| Metric | RELY | TMDX |
|---|---|---|
| Price | $13.47 | $136.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $26.00 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 4.1M | 835.5K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | 0.09 | ★ 2.54 |
| Revenue | ★ $1,544,865,000.00 | $566,354,000.00 |
| Revenue This Year | $30.78 | $38.84 |
| Revenue Next Year | $18.39 | $20.43 |
| P/E Ratio | $142.50 | ★ $53.83 |
| Revenue Growth | 31.27 | ★ 41.20 |
| 52 Week Low | $12.08 | $55.00 |
| 52 Week High | $27.32 | $156.00 |
| Indicator | RELY | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 54.31 |
| Support Level | $12.88 | $133.50 |
| Resistance Level | $13.59 | $156.00 |
| Average True Range (ATR) | 0.40 | 8.50 |
| MACD | 0.21 | 0.41 |
| Stochastic Oscillator | 75.34 | 55.98 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.